Uncategorized
Ocular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), today presented data at ARVO evaluating the efficacy, tolerability and pharmacokinetics of its sustained release intravitreal tyrosine kinase inhibitor (TKI).